These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15473158)

  • 1. Risk of fatal adverse events associated with 17DD yellow fever vaccine.
    Struchiner CJ; Luz PM; Dourado I; Sato HK; Aguiar SG; Ribeiro JG; Soares RC; Codeço CT
    Epidemiol Infect; 2004 Oct; 132(5):939-46. PubMed ID: 15473158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
    Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
    Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
    Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
    J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
    Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
    Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
    Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
    Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.
    Engel AR; Vasconcelos PF; McArthur MA; Barrett AD
    Vaccine; 2006 Apr; 24(15):2803-9. PubMed ID: 16464518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
    Marchevsky RS; Freire MS; Coutinho ES; Galler R
    Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A public health risk assessment for yellow fever vaccination: a model exemplified by an outbreak in the state of São Paulo, Brazil.
    Ribeiro AF; Tengan C; Sato HK; Spinola R; Mascheretti M; França AC; Port-Carvalho M; Pereira M; Souza RP; Amaku M; Burattini MN; Coutinho FA; Lopez LF; Massad E
    Mem Inst Oswaldo Cruz; 2015 Apr; 110(2):230-4. PubMed ID: 25946247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sero-prevalence of yellow fever and related Flavi viruses in Ethiopia: a public health perspective.
    Mengesha Tsegaye M; Beyene B; Ayele W; Abebe A; Tareke I; Sall A; Yactayo S; Shibeshi ME; Staples E; Belay D; Lilay A; Alemu A; Alemu E; Kume A; H/Mariam A; Ronveaux O; Tefera M; Kassa W; Bekele Weyessa A; Jima D; Kebede A; Tayachew A
    BMC Public Health; 2018 Aug; 18(1):1011. PubMed ID: 30107830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Risk and Elimination of Yellow Fever Epidemics.
    Ndeffo-Mbah ML; Pandey A
    J Infect Dis; 2020 Jun; 221(12):2026-2034. PubMed ID: 31545372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17DD Yellow Fever Revaccination and Heightened Long-Term Immunity in Populations of Disease-Endemic Areas, Brazil.
    Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LR; Costa-Pereira C; Speziali E; Reis LR; Lemos JA; Ribeiro JGL; Bastos Camacho LA; de Sousa Maia ML; Barbosa de Lima SM; Simões M; de Menezes Martins R; Homma A; Cota Malaquias LC; Tauil PL; Costa Vasconcelos PF; Martins Romano AP; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    Emerg Infect Dis; 2019 Aug; 25(8):1511-1521. PubMed ID: 31298654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.